Earnings Releases·Nov 9, 2026, 7:20 AM ET

Tonix Pharmaceuticals — Third Quarter 2026 Earnings Summary

Net product revenue surged to $17.2 million from $3.3 million year-over-year, driven by $15.0 million in TONMYA sales, while net loss narrowed to $53.3 million ($2.89/share) from $32.0 million ($3.59/share) in the prior year period.
Cash reserves decreased to $163 million as of September 30, 2026, with management projecting liquidity sufficient to fund operations and capital expenditures into early Q3 2027, supported by $1.5 million in subsequent equity offerings.
TONMYA commercial momentum accelerated with a 28% quarter-over-quarter increase in total prescriptions and expanded payer access covering ~166 million lives, alongside a sales force expansion to 150 representatives.
Pipeline progress includes an expected adaptive Phase 2 TRAIL study for TNX-4800 and a Phase 2 investigator-initiated study for TNX-1500 to commence in Q1 2027, pending FDA protocol agreement.
The company faces a Paragraph IV patent certification challenge from Dr. Reddy's Laboratories regarding TONMYA filed in October 2026, with management committed to vigorously enforcing intellectual property rights.